Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
If your prescription is approved and your medication ships, the order is non-refundable
Limit usage to 23 times a week for safe and effective results
COA / Lab results Evidence: Clinical trial Pros Triple GLP-1 / GIP / glucagon agonism in one peptide raises energy expenditure, not appetite alone Largest weight reduction reported for an incretin-class compound (~24% at 12 mg, 48-wk phase 2) Reductions in HbA1c, visceral fat and liver-fat content across trials Once-weekly subcutaneous dosing (albumin-bound half-life) Cons GI effects require gradual multi-week dose titration Newest of the GLP-1 class phase 3 (TRIUMPH) topline only
Beyond weight loss: the disease-modifying potential of GLP-1s Mike Haney: So mechanistically it sounds like the outcome is the same as what we would be trying to achieve with lifestyle which is essentially negative energy balance
Obesity 31 , 23862397 (2023)
